Abstract
Peripheral arterial occlusive disease (PAD) describes vascular disorders associated with ischemia and PAD affects about 8 million people in the United States. Moreover, PADs prevalence can increase dramatically if cardiovascular disease is present. In healthy individuals reducing blood flow through the lower extremity is followed by a physiological process to limit ischemia in the distal tissue. This process is called revascularization and impairing revascularization results in PAD. Studies suggest nitric oxide (NO) maybe involved in the ischemia-dependent hindlimb revascularization process. NO is increased in the ischemic hindlimb and eliminating NO impairs the revascularization process. Moreover, restoring NO improves hindlimb revascularization. NO may be acting through its effects on vascular tone, cell migration, or extracellular matrix degradation. The present review illustrates nitric oxides critical role in the ischemia-induced hindlimb revascularization. Thus, restoring normal NO levels in diseased arteries may represent a viable therapeutic avenue by supplementing exogenous NO or employing therapeutic strategies to either increase NO synthesis and its messengers or decrease NO catabolism.
Keywords: Angiogenesis, arteriogenesis, nitric oxide, revasculatization, peripheral arterial disease
Current Pharmaceutical Design
Title: Nitric Oxide-Dependent Neovascularization Role in the Lower Extremity Disease
Volume: 13 Issue: 35
Author(s): Monica G. Arellano Mendoza, Hilda Vargas Robles, Eunice Romo, Amelia Rios and Bruno Escalante
Affiliation:
Keywords: Angiogenesis, arteriogenesis, nitric oxide, revasculatization, peripheral arterial disease
Abstract: Peripheral arterial occlusive disease (PAD) describes vascular disorders associated with ischemia and PAD affects about 8 million people in the United States. Moreover, PADs prevalence can increase dramatically if cardiovascular disease is present. In healthy individuals reducing blood flow through the lower extremity is followed by a physiological process to limit ischemia in the distal tissue. This process is called revascularization and impairing revascularization results in PAD. Studies suggest nitric oxide (NO) maybe involved in the ischemia-dependent hindlimb revascularization process. NO is increased in the ischemic hindlimb and eliminating NO impairs the revascularization process. Moreover, restoring NO improves hindlimb revascularization. NO may be acting through its effects on vascular tone, cell migration, or extracellular matrix degradation. The present review illustrates nitric oxides critical role in the ischemia-induced hindlimb revascularization. Thus, restoring normal NO levels in diseased arteries may represent a viable therapeutic avenue by supplementing exogenous NO or employing therapeutic strategies to either increase NO synthesis and its messengers or decrease NO catabolism.
Export Options
About this article
Cite this article as:
Arellano Mendoza G. Monica, Robles Vargas Hilda, Romo Eunice, Rios Amelia and Escalante Bruno, Nitric Oxide-Dependent Neovascularization Role in the Lower Extremity Disease, Current Pharmaceutical Design 2007; 13 (35) . https://dx.doi.org/10.2174/138161207782794103
DOI https://dx.doi.org/10.2174/138161207782794103 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Exploring New CGRP Family Peptides and their Receptors in Vertebrates
Current Protein & Peptide Science The Role of Neuropeptides and Neurohormones in Neurogenic Cardiac Arrhythmias
Current Drug Targets - Cardiovascular & Hematological Disorders Farnesoid-X Receptor (FXR) as a Promising Pharmaceutical Target in Atherosclerosis
Current Medicinal Chemistry Transport of Cryptotanshinone, a Major Active Triterpenoid in Salvia Miltiorrhiza Bunge Widely Used in the Treatment of Stroke and Alzheimers Disease, Across the Blood-Brain Barrier
Current Drug Metabolism Nosocomial Infections and Antimicrobial Treatment in Coiled Patients with Aneurysmal Subarachnoid Hemorrhage
Current Drug Targets Pigment Epithelium-Derived Factor: A Novel Therapeutic Target for Cardiometabolic Diseases and Related Complications
Current Medicinal Chemistry NPY and Cardiac Diseases
Current Topics in Medicinal Chemistry Recent Valves used for Transluminal Implantation in Patients with Aortic Valve Stenosis
Recent Patents on Cardiovascular Drug Discovery HDL Apolipoprotein-Related Peptides in the Treatment of Atherosclerosis and other Inflammatory Disorders
Current Pharmaceutical Design A Review of the Cardiovascular and Anti-Atherogenic Effects of Ghrelin
Current Pharmaceutical Design Enhanced Selectivity Screening of GPCR Ligands Using a Label-Free Cell Based Assay Technology
Combinatorial Chemistry & High Throughput Screening Diabetes Mellitus and Vascular Endothelial Dysfunction: Current Perspectives
Current Vascular Pharmacology Deletion of Endoplasmic Reticulum Stress-Induced CHOP Protects Microvasculature Post-Spinal Cord Injury
Current Neurovascular Research Nanocarriers for Tracking and Treating Diseases
Current Medicinal Chemistry Patent Selections
Recent Patents on Cardiovascular Drug Discovery Crosstalk Signalling Role in Modulation of Drugs Side Effects
Current Molecular Pharmacology Calcific Aortic Valve Disease and Hypertension
Current Hypertension Reviews Beneficial Effects of N-acetylcysteine and N-mercaptopropionylglycine on Ischemia Reperfusion Injury in the Heart
Current Medicinal Chemistry Editorial (Thematic Issue: Antiplatelet Treatment in Cardiovascular Disease: New Insights)
Current Pharmaceutical Design Potassium Channels as Targets for the Management of Pain
Central Nervous System Agents in Medicinal Chemistry